2-(3-Aminopropyl)-5-fluoro-3-phenylquinazolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(3-Aminopropyl)-5-fluoro-3-phenylquinazolin-4-one
• 英文别名: 2-(3-aminopropyl)-5-fluoro-3-phenylquinazolin-4-one
• 化学式: C₁₇H₁₆FN₃O
• 分子量: 297.33
• InChiKey: GDGJFGPJJHPFLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB<br/>[FR] PROCÉDÉ DE PRÉPARATION D'IDÉLALISIB AMORPHE
  申请人：NATCO PHARMA LTD

  公开号：WO2018198131A1

  公开（公告）日：2018-11-01

  The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.

  本发明涉及一种制备Idelalisib稳定和纯的非晶形态的方法。此外，本方法简单、更经济、成本效益高，是一种适合工业规模扩大且具有高度色谱纯度的高效制造方法。
• [EN] PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB AND ITS PREMIX<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'IDÉLALISIB AMORPHE ET SON MÉLANGE PRÉLIMINAIRE
  申请人：MYLAN LABORATORIES LTD

  公开号：WO2016147206A1

  公开（公告）日：2016-09-22

  Processes for the preparation of amorphous idelalisib are provided. Processes for the preparation of a premix of amorphous idelalisib are also provided.

  提供了制备非晶态idelalisib的过程。还提供了制备非晶态idelalisib预混物的过程。
• [EN] SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE À SUBSTITUTION 2-AMINO SERVANT DE COMPOSÉS INHIBITEURS DE KINASE
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014106800A2

  公开（公告）日：2014-07-10

  The present invention provides novel substituted 2-amino pyrimidine derivatives kinase enzyme inhibitor compounds of formula (1), which may be therapeutically useful kinase inhibitor, more particularly PI3K inhibitors. Formula (1) in which A, R1, R2 R3. R4, Q and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly PI3K enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.